Most patients lose 28 pounds in the first month, with the first 25 pounds appearing by week 34
A mild tendonitis protocol differs from a post-surgical recovery protocol even when using the same peptide
The New England Journal of Medicine commentary accompanying SURPASS-2 stated: "The dual incretin approach appears to exploit receptor crosstalk in ways that amplify downstream insulin secretion beyond what GLP-1 receptor agonism alone can achieve at comparable tolerability." [30] SURPASS-1: Monotherapy Benchmark SURPASS-1 (N=478) established monotherapy efficacy, with tirzepatide 15 mg reducing A1C by 2.07 percentage points and body weight by 9.5 kg at 40 weeks versus placebo [31]
The common thread: none of these work in isolation, and none of them replace the fundamentals (caloric deficit, protein, training, sleep)
Underlying sleep disorders Many people taking Mounjaro have excess weight, which is closely linked to sleep apnea and other sleep disorders
Additionally, lowered BCAAs availability and/or inhibition of valine degradation in prostate cancer cells diminished lipid metabolism
